DR. REDDY'S LABORATORIES-ADR (RDY) Stock Price, Forecast & Analysis

NYSE:RDY • US2561352038

14.38 USD
-0.2 (-1.37%)
At close: Feb 27, 2026
14.38 USD
0 (0%)
After Hours: 2/27/2026, 8:04:00 PM

RDY Key Statistics, Chart & Performance

Key Statistics
Market Cap11.97B
Revenue(TTM)346.82B
Net Income(TTM)57.72B
Shares832.57M
Float587.34M
52 Week High16.17
52 Week Low12.26
Yearly Dividend0.09
Dividend Yield0.61%
EPS(TTM)0.73
PE19.7
Fwd PE22.9
Earnings (Next)05-07
IPO1986-01-01
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
RDY short term performance overview.The bars show the price performance of RDY in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 2 4 6 8

RDY long term performance overview.The bars show the price performance of RDY in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 20 30

The current stock price of RDY is 14.38 USD. In the past month the price increased by 8.36%. In the past year, price increased by 12.52%.

DR. REDDY'S LABORATORIES-ADR / RDY Daily stock chart

RDY Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to RDY. When comparing the yearly performance of all stocks, RDY turns out to be only a medium performer in the overall market: it outperformed 59.38% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
RDY Full Technical Analysis Report

RDY Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to RDY. RDY scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RDY Full Fundamental Analysis Report

RDY Financial Highlights

Over the last trailing twelve months RDY reported a non-GAAP Earnings per Share(EPS) of 0.73. The EPS increased by 3.81% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.82%
ROA 10.62%
ROE 16.03%
Debt/Equity 0.03
Chartmill High Growth Momentum
EPS Q2Q%-14.29%
Sales Q2Q%4.44%
EPS 1Y (TTM)3.81%
Revenue 1Y (TTM)11.06%
RDY financials

RDY Forecast & Estimates

44 analysts have analysed RDY and the average price target is 15.24 USD. This implies a price increase of 5.97% is expected in the next year compared to the current price of 14.38.

For the next year, analysts expect an EPS growth of -6.34% and a revenue growth 6.48% for RDY


Analysts
Analysts67.27
Price Target15.24 (5.98%)
EPS Next Y-6.34%
Revenue Next Year6.48%
RDY Analyst EstimatesRDY Analyst Ratings

RDY Ownership

Ownership
Inst Owners49.42%
Ins Owners1.23%
Short Float %2.13%
Short Ratio8.05
RDY Ownership

RDY Latest News, Press Relases and Analysis

All RDY news

RDY Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
LLY ELI LILLY & CO31.34994.53B
JNJ JOHNSON & JOHNSON21.32598.542B
MRK MERCK & CO. INC.22.88307.324B
PFE PFIZER INC9.21157.21B
BMY BRISTOL-MYERS SQUIBB CO10.25126.97B
ZTS ZOETIS INC19.0957.775B
RPRX ROYALTY PHARMA PLC- CL A8.9126.674B
VTRS VIATRIS INC5.917.196B
ELAN ELANCO ANIMAL HEALTH INC25.2513.117B
AXSM AXSOME THERAPEUTICS INC200.128.262B

About RDY

Company Profile

RDY logo image Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Company Info

DR. REDDY'S LABORATORIES-ADR

8-2-337, Road No.3 Banjara Hills

Hyderabad TELANGANA 500-034 IN

CEO: Erez Israeli

Employees: 26944

RDY Company Website

RDY Investor Relations

Phone: 914049002900

DR. REDDY'S LABORATORIES-ADR / RDY FAQ

What does DR. REDDY'S LABORATORIES-ADR do?

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. The company is headquartered in Hyderabad, Telangana and currently employs 26,944 full-time employees. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. The company works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.


What is the stock price of DR. REDDY'S LABORATORIES-ADR today?

The current stock price of RDY is 14.38 USD. The price decreased by -1.37% in the last trading session.


Does RDY stock pay dividends?

DR. REDDY'S LABORATORIES-ADR (RDY) has a dividend yield of 0.61%. The yearly dividend amount is currently 0.09.


How is the ChartMill rating for DR. REDDY'S LABORATORIES-ADR?

RDY has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


Can you provide the PE ratio for RDY stock?

The PE ratio for DR. REDDY'S LABORATORIES-ADR (RDY) is 19.7. This is based on the reported non-GAAP earnings per share of 0.73 and the current share price of 14.38 USD.


Can you provide the upcoming earnings date for DR. REDDY'S LABORATORIES-ADR?

DR. REDDY'S LABORATORIES-ADR (RDY) will report earnings on 2026-05-07, after the market close.


What is the outstanding short interest for DR. REDDY'S LABORATORIES-ADR?

The outstanding short interest for DR. REDDY'S LABORATORIES-ADR (RDY) is 2.13% of its float.